Overview of Dr. Jagannath
Dr. Sundar Jagannath is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including The Mount Sinai Hospital and Mount Sinai West. He received his medical degree from Baroda Medical College and has been in practice 41 years. Dr. Jagannath accepts several types of health insurance, listed below. He is one of 189 doctors at The Mount Sinai Hospital and one of 74 doctors at Mount Sinai West who specialize in Oncology. He has more than 100 publications and over 500 citings.
Office
10 E 102nd St
New York, NY 10029Fax+1 212-241-3908
Education & Training
- University of Texas Health Science Center at HoustonResidency, Internal Medicine, 1980 - 1982
- Wayne State University School of MedicineResidency, Internal Medicine, 1979 - 1980
- BronxCare Health SystemResidency, Internal Medicine, 1977 - 1979
- Baroda Medical CollegeClass of 1976
Certifications & Licensure
- FL State Medical License 2017 - 2025
- NJ State Medical License 2017 - 2025
- NY State Medical License 1998 - 2025
- MI State Medical License 1979 - 2020
- TX State Medical License 1980 - 2011
- AR State Medical License 1989 - 2000
- MD State Medical License 1979 - 1992
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Top Doctors: New York Metro Area Castle Connolly, 2002-2014
- New York Magazine: Top Doctors Castle Connolly, 2004, 2013
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
- Join now to see all
Clinical Trials
- Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma Start of enrollment: 2005 Jun 01
- Phase I Study for Safety and Efficacy of P276-00 in Subjects With Myeloma Start of enrollment: 2008 Dec 01
- An Open-label, Dose-escalation Safety and Tolerability Trial Assessing Anti-KIR (1-7F9) in Subjects With Multiple Myeloma Start of enrollment: 2007 May 01
- Join now to see all
Publications & Presentations
PubMed
- 1594 citationsAn inflammatory cytokine signature predicts COVID-19 severity and survival.Diane Marie Del Valle, Seunghee Kim-Schulze, Hsin-Hui Huang, Noam D. Beckmann, Sharon Nirenberg
Nature Medicine. 2020-08-24 - 215 citationsCiltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Fol...Thomas Martin, Saad Z Usmani, Jesus G Berdeja, Mounzer Agha, Adam D Cohen
Journal of Clinical Oncology. 2023-02-20 - 173 citationsPembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.Maria-Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold, Albert Oriol, David Simpson
The Lancet. Haematology. 2019-07-18
Abstracts/Posters
- A Machine Learning Approach Identifies a 30-Gene Model That Predicts Sensitivity to Selinexor in Multiple MyelomaSundar Jagannath, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Selinexor-Containing Regimens for the Treatment of Patients with Multiple Myeloma Refractory to Chimeric Antigen Receptor T-Cell (CAR-T) TherapySundar Jagannath, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Results of a Phase I Study of Pnk-007, Allogeneic, Off the Shelf NK Cell, Post Autologous Transplant in Multiple Myeloma (NCT02955550)Sundar Jagannath, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Authored Content
- Blood Transfusion Management and Transfusion-Related Outcomes in Daratumumab-Treated Patients with Relapsed or Refractory Multiple MyelomaJune 2016
Press Mentions
- Caribou Biosciences Announces FDA Clearance of IND Application for CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple MyelomaNovember 21st, 2022
- Ciltacabtagene Autoleucel in Relapsed or Refractory Multiple Myeloma: 2-Year Follow-up of CARTITUDE-1 TrialJune 9th, 2022
- Carvykti Approved for Relapsed/Refractory Multiple MyelomaMarch 2nd, 2022
- Join now to see all
Professional Memberships
- Member
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
GHI PPO
Great West PPOHIP of New York - Select PPO
Humana ChoiceCare Network PPO
MagnaCare PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: